• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France
【24h】

Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France

机译：带草花粉片的免疫疗法减少了对过敏性鼻炎和哮喘的药物分配：法国的回顾性数据库研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background Moderate‐to‐severe allergic rhinitis ( AR ) may increase the risk of developing or worsening asthma, whereas treatment of AR with subcutaneously or sublingual allergen immunotherapy ( SLIT ) may slow this progression. Methods In a retrospective real‐world analysis, prescription fulfilment data were gathered from French retail pharmacies between 1 March 2012 and 31 December 2016. Using linear regression analyses, patients having received at least two prescriptions of grass pollen SLIT tablets over at least 2 successive years were compared with control patients having received symptomatic medications only. Results A total of 1099 SLIT patients and 27?475 control patients were included in the main analysis. With regard to symptomatic AR medication dispensing, we observed a 50% decrease in the pre‐index/follow‐up ratio in the SLIT group, a 30% increase in the control group without age matching ( P ??0.0001 vs SLIT ) and a 20% increase in the control group with age matching ( P ??0.0001 vs SLIT ). During the follow‐up, 11 (1.8%) and 782 (5.3%) patients initiated asthma treatment in the SLIT and control groups, respectively. The relative risk of medication dispensing for new asthma was lower in the SLIT group (by 62.5% [29.1%‐80.1%] without age matching ( P ?=?0.0025) and by 63.7% [31.5%‐80.7%] with age matching; P ?=?0.0018). SLIT was also associated with slower progression of asthma medication dispensing during the follow‐up period, relative to the control group (regression coefficient: ?0.58 [?0.74 to 0.42] without age matching ( P ??0.0001) and ?0.61 [?0.76 to ?0.46] with age matching; P ??0.0001). Conclusion Prescription of grass pollen SLIT tablets reduced the dispensing of AR and asthma medications in real life.
机译：摘要背景，中度至严重的过敏性鼻炎（AR）可能会增加哮喘发育或恶化的风险，而用皮下或舌下过敏原免疫疗法（缝隙）治疗AR可能会减缓这种进展。方法在回顾性实际分析中，处方履行数据从2012年3月1日和2016年12月31日之间从法国零售药房收集。使用线性回归分析，患者在至少2年内接受了至少两种草花粉狭缝片的患者与仅接受症状药物的对照患者进行比较。结果总共1099例患者和27例，475例控制患者均被纳入主要分析。关于症状的AR药物分配，我们观察到狭缝基团的预指数/随访比率下降50％，对照组的增加30％而没有年龄匹配（P？＆？0.0001 vs狭缝）具有年龄匹配的对照组增加了20％（P？＆？0.0001 Vs狭缝）。在随访期间，11（1.8％）和782名（5.3％）患者分别在狭缝和对照组中发起哮喘治疗。在狭缝基团中较新哮喘药物分配的相对风险较低（达到62.5％[29.1％-80.1％]，没有年龄匹配（p？= 0.0025），随着年龄匹配的63.7％[31.5％-80.7％] ; p？= 0.0018）。相对于对照组（回归系数：α0.58[0.74至0.42]而没有年龄匹配，狭缝也与哮喘药物分配较慢的进展相关联α0.76至0.46]年龄匹配; p？＆？0.0001）。结论草花粉狭缝片的处方降低了现实生活中AR和哮喘药物的分配。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号